阿瑞匹坦适用人群及用法用量

Aprepitant (trade name: Italian-American) has a unique mode of action. It is a selective and high-affinity antagonist to the receptor of human substance P Neurokinin1 (NK1). Preclinical studies have shown that aprepitant can penetrate into the brain and bind to the brain's NK1 receptor. Preclinical studies have shown that it has a long-lasting effect on the central system and can inhibit vomiting in the acute and delayed phases caused by cisplatin, thereby enhancing the antiemetic 5-HT3-receptor antagonist ondansetron and the leather steroid dexamethasone against cisplatin-induced vomiting.

Aprepitant is suitable for the prevention of acute and delayed nausea and vomiting during initial and repeated treatment with highly emetogenic anti-tumor chemotherapy. Aprepitant is the first NK-1 receptor antagonist, which binds highly selectively to NK-1 receptors in the brain and antagonizes substance P. Substance P is a neurokinin located in the nerves of the central and peripheral nervous systems. It acts through NK-1 receptors and is related to various inflammatory immune responses such as vomiting, depression, pain and asthma. As a first-line drug and recommended drug for preventing nausea and vomiting caused by highly emetogenic anti-tumor chemotherapy, aprepitant has been unanimously recommended by authoritative European and American guidelines such as the National Comprehensive Cancer Network Clinical Application Guidelines (NCCN).

According to the instructions, the dosage of aprepitant is as follows: 125 mg orally taken 1 hour before chemotherapy, and 80 mg taken in the morning on days 2 and 3. 40m is used to prevent vomiting 3 hours before anesthesia surgery. Please refer to the instructions for details. Please read the instruction manual for details. The contents of the instruction manual shall prevail. : Aprepitant capsules were administered for 3 days in combination with a corticosteroid and a 5-HT3 antagonist. Read the instructions for your 5-HT3 antagonist carefully before starting treatment. The recommended dose is 125 mg orally administered 1 hour before chemotherapy (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.